New triple-drug attack targets stubborn colorectal cancer
NCT ID NCT06784947
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 26 times
Summary
This study tests a combination of three drugs (tiragolumab, atezolizumab, and bevacizumab) in 13 people with advanced colorectal cancer that has not responded to prior treatment and is microsatellite stable (a type that typically does not respond to immunotherapy alone). The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs and are monitored with scans and lab tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Universtiy of Colorado Hospital
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.